Abstract
Preliminary results from FLAGSHP-1: A phase 1 study of ERAS-601 as a monotherapy or in combination with cetuximab in patients (pts) previously treated for advanced chordoma.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have